Intrapleural bupivacaine v saline after thoracotomy--effects on pain and lung function--a double-blind study.
The effects of intrapleural (IP) bupivacaine on pain, morphine requirement, and pulmonary function were evaluated in 15 patients for 24 hours after thoracotomy. An IP catheter was placed during surgery. Patients were randomized in a double-blind fashion to receive 1.5 mg/kg of 0.5% bupivacaine IP or saline on two occasions, eight hours apart. A standard anesthetic with thiopental, oxygen, isoflurane, and nondepolarizing muscle relaxant was given. Pain was evaluated with a visual analog pain score every hour, and forced vital capacity (FVC), forced expiratory volume one second (FEV1), peak expiratory flow (PF), and forced expiratory flow 25% to 75% (FEF) were measured 1, 2, 4, 8, and 24 hours postoperatively as well as before and 30 minutes after each IP injection. Arterial blood gases were sampled 1, 2, 8, and 24 hours postoperatively. Plasma bupivacaine concentrations were measured in 10 patients 5, 10, 20, 30, 60, 120, and 180 minutes after IP injection. With each IP bupivacaine injection, the pain score and morphine requirement decreased. There was a significant improvement in all pulmonary function tests in the patients receiving bupivacaine, but no change in the saline controls. The analgesic effect was shortlived (two to five hours), possibly because of loss of bupivacaine in the chest drains. No differences were seen between the two groups after the effect of IP bupivacaine had worn off. Plasma bupivacaine levels had a Cmax of 0.44 to 1.50 micrograms/mL, with a Tmax at 5 to 30 minutes with levels well below 2 to 4 micrograms/mL where increasing toxicity is seen.
Symreng
T
T
Department of Anesthesia, University of Iowa Hospital and Clinics, Iowa City, IA 52242.
Gomez
M N
MN
Rossi
N
N
D000368:Aged; D000369:Aged, 80 and over; D000698:Analgesia / Q000295:instrumentation / Q000379:methods*; D000704:Analysis of Variance; D002045:Bupivacaine / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D002404:Catheterization / Q000295:instrumentation; D004311:Double-Blind Method; D005260:Female; D005540:Forced Expiratory Flow Rates / Q000502:physiology; D005541:Forced Expiratory Volume / Q000502:physiology; D006801:Humans; D008168:Lung / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010149:Postoperative Pain / Q000503:physiopathology / Q000517:prevention & control*; D010919:Placebos; D010994:Pleura; D012965:Sodium Chloride; D013908:Thoracotomy; D014797:Vital Capacity / Q000502:physiology
D010919:Placebos; D012965:Sodium Chloride; D002045:Bupivacaine